View Item 

Show simple item record

The t(2;5)-;associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders
dc.contributor.authorSu, Lyndon D.en_US
dc.contributor.authorSchnitzer, Bertramen_US
dc.contributor.authorRoss, Charles W.en_US
dc.contributor.authorVasef, Mohammaden_US
dc.contributor.authorMori, Shigeoen_US
dc.contributor.authorShiota, Mamien_US
dc.contributor.authorMason, David Y.en_US
dc.contributor.authorPulford, Karenen_US
dc.contributor.authorHeadington, John T.en_US
dc.contributor.authorSingleton, Timothy P.en_US
dc.date.accessioned2010-06-01T21:08:26Z
dc.date.available2010-06-01T21:08:26Z
dc.date.issued1997-11en_US
dc.identifier.citationSu, Lyndon D.; Schnitzer, Bertram; Ross, Charles W.; Vasef, Mohammad; Mori, Shigeo; Shiota, Mami; Mason, David Y.; Pulford, Karen; Headington, John T.; Singleton, Timothy P. (1997). "The t(2;5)-;associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders." Journal of Cutaneous Pathology 24(10): 597-603. <http://hdl.handle.net/2027.42/74223>en_US
dc.identifier.issn0303-6987en_US
dc.identifier.issn1600-0560en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74223
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=9449486&dopt=citationen_US
dc.format.extent9902488 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights1997 Munksgaarden_US
dc.titleThe t(2;5)-;associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disordersen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherCity of Hope National Medical Center, Duarte, Californiaen_US
dc.contributor.affiliationotherUniversity of Tokyo, Tokyo, Japanen_US
dc.contributor.affiliationotherJohn Radcliffe Hospital, Oxford, UKen_US
dc.identifier.pmid9449486en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74223/1/j.1600-0560.1997.tb01090.x.pdf
dc.identifier.doi10.1111/j.1600-0560.1997.tb01090.xen_US
dc.identifier.sourceJournal of Cutaneous Pathologyen_US
dc.identifier.citedreferenceMorris S, Kirstein M, Valentine M, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994: 203: 1281.en_US
dc.identifier.citedreferenceHerbst H, Anagnostopoulos J, Heinze B, Durkop H, Hummel M, Stein H. ALK gene products in anaplaslic large cell lymphomas and Hodgkin's disease. Blood 1995: 86: 1694.en_US
dc.identifier.citedreferenceWood G, Hardman D, Boni R, et al. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Blood 1996: 88: 1765.en_US
dc.identifier.citedreferenceFujimoto J, Shiota M, Iwahara T, et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci 1996: 93: 4181.en_US
dc.identifier.citedreferenceShiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80 NPM/ALK: A distinct clinicopathologic entity. Blood 1995: 86: 1954.en_US
dc.identifier.citedreferenceShiota M, Fujimoto J, Takenaga M, et al. Diagnosis of t(2;5) (p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 1994: 84: 3648.en_US
dc.identifier.citedreferenceDeCoteau J, Butmare J, Kinney M, Kadin M. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: Comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996: 87: 3437.en_US
dc.identifier.citedreferenceBeylot-Barry M, Lamant L, Vergier B, et al. Detection of t(2;5) (p23;q35) translocation by reverse transcriptase polymerase chain reaction and in-situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol 1996: 149: 483.en_US
dc.identifier.citedreferenceLamant L, Meggetto F, Saati T, et al. High incidence of the t(2;5) (p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and p80 immunostaining. Blood 1996: 87: 284.en_US
dc.identifier.citedreferencePulford K, Lamant L, Morris S, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK-1. Blood 1997: 89: 1394.en_US
dc.identifier.citedreferenceDelsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997: 89: 1483.en_US
dc.identifier.citedreferenceBruin P, Beljaards R, Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology 1993: 23: 127.en_US
dc.identifier.citedreferenceBeljaards R, Kaudewitz P, Berti E, et al. Primary cutaneous CD30-posilive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. Cancer 1993: 71: 2097.en_US
dc.identifier.citedreferenceLopategui J, Sun L, Chan J, et al. Low frequency association of the t(2;5) (p23;q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients. Am J Pathol 1995: 146: 323.en_US
dc.identifier.citedreferenceSarris A, Luthra R, Papadimitracopoulou V, et al. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood 1996: 88: 1771.en_US
dc.identifier.citedreferenceWellman A, Otsuki T, Vogelbruch M, Clark H, Jaffe E, Raffeld M. Analysis of the t(2;5) (p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in oilier non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease. Blood 1995: 86: 2321.en_US
dc.identifier.citedreferenceWillemze R, Beljaards R. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders – a proposal for classification and guidelines for management and treatment. Am Acad Dermatol 1993: 28: 973.en_US
dc.identifier.citedreferenceStein H, Dallenbach F. Diffuse large cell lymphomas of B and T cell type. In: Knowles DM, ed. Neoplastic Hematopathology. Baltimore: Williams & Wilkins, 1992: 698.en_US
dc.identifier.citedreferencePaulli M, Emilio B, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin – clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 1995: 13: 1343.en_US
dc.identifier.citedreferenceShi SR, Key ME, Kalra K. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991: 39: 741.en_US
dc.identifier.citedreferenceDeCoteau J, Kinney M, Kadin M. Presence of t(2;5) in primary CD30+ cutaneous lymphoproliferative disorders. Blood 1996: 88: 3240.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-0560.1997.tb01090.x.pdf
Size:
9.443MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.